0.00
0.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Scorpius Holdings
Its shares trade under the ticker SCPX. It has been listed since 24 July 2013. In the fiscal year to 31 December 2024, it reported revenue of $6.2m and a net loss of $32.8m. At that date it held total assets of $39.2m and shareholders' equity of $6.3m.
Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company is headquartered in Morrisville, North Carolina. The company went IPO on 2013-07-24. The firm is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. The company is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 24 Jul 2013
- Employees
- 89
- Website
- heatbio.com ↗
- Head office
- 1305 E. HOUSTON STREET, SAN ANTONIO, TX, 78205
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Jeffrey WolfChairman of the Board, President, Chief Executive Officer, since 2008$578,995
- Mr. William OstranderChief Financial Officer, Secretary$376,997
- Mr. Kit Foo ChyeDirector
- Dr. John MonahanIndependent Director$81,500
- Mr. Edward SmithIndependent Director$92,500
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- HS-410 targets non-muscle invasive bladder cancer using the ImPACT platform technology.
- HS-110 combines with nivolumab to treat non-small cell lung cancer patients.
- HS-120 utilizes ComPACT technology for potential non-small cell lung cancer treatment.
Weaknesses
- The company employs only 39 full-time staff members in Morrisville.
- Scorpius Holdings Inc operates with a small workforce of 89 employees.
- HS-410 is currently in Phase II trials for bladder cancer treatment.
Opportunities
- HS-110 shows potential when combined with anti-PD-1 checkpoint inhibitors for NSCLC.
- ImPACT platform technology activates T-cell mediated immune systems against cancer effectively.
- ComPACT platform offers new avenues for treating non-small cell lung cancer.
Threats
- HS-110 trials rely on combination therapy with nivolumab for efficacy.
- Phase Ib trials for HS-110 face competition in the immunotherapy market.
- Non-small cell lung cancer treatments require rigorous clinical validation for success.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.